Pharmacologic METTL3 inhibition attenuates TGF-beta-driven profibrotic signature in systemic sclerosis
Nikolaos I. Vlachogiannis, Simon Tual‐Chalot, Maria Polycarpou‐Schwarz, Elly Wu, Aikaterini-Paraskevi Avdi, Kateryna Sopova, Marco Sachse, Stylianos Panopoulos, Maria G. Tektonidou, Kimon Stamatelopoulos, Athanasios Zovoilis, Petros Paul Sfikakis, Konstantinos Stellos
This study identifies an m6A epitranscriptomic signature in systemic sclerosis that drives profibrotic changes, which can be reversed by METTL3 inhibition.
bioRxiv · Sep 13, 2026 · PreprintMolecular Biology